V21I (p.Val21Ile) variant of NTRK3 (NT-3 growth factor receptor)

V21I (p.Val21Ile) in NTRK3 (NT-3 growth factor receptor) is a missense change. Clinical records from EBI and UniProt describe it as likely benign. The available variant effect predictions contribute to a CATVariant prioritization score of 0.22 / 1. The record also includes population frequency data and structural context.

V21I (p.Val21Ile) variant details